The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis
Article first published online: 27 FEB 2014
© 2014 John Wiley & Sons Ltd
Diabetes, Obesity and Metabolism
Volume 16, Issue 8, pages 707–710, August 2014
How to Cite
Zhang, Z.-J. and Li, S. (2014), The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism, 16: 707–710. doi: 10.1111/dom.12267
- Issue published online: 15 JUL 2014
- Article first published online: 27 FEB 2014
- Accepted manuscript online: 27 JAN 2014 02:12AM EST
- Manuscript Accepted: 19 JAN 2014
- Manuscript Revised: 5 JAN 2014
- Manuscript Received: 28 NOV 2013
- Wuhan University. Grant Number: 305273821
- cancer-specific survival;
Emerging evidence from epidemiologic studies and basic science suggests a potential antitumour effect of metformin. However, whether metformin improves survival in cancer patients remains inconclusive.
A literature search was performed using the PubMed, EMbase and SciVerse Scopus databases. Pooled effect estimates were derived using a random-effects meta-analysis model.
Of the 28 studies retrieved, the pooled effect estimates showed that metformin was associated with lower risk of all-cause mortality in cancer patients with concurrent diabetes, particularly for breast [pooled relative risk (RR) 0.70, 95% CI 0.55, 0.88; p = 0.003], colorectal (RR 0.70, 95% CI 0.59, 0.84; p < 0.001), ovarian (RR 0.44, 95% CI 0.30, 0.64; p < 0.001) and endometrial cancer (RR 0.49, 95% CI 0.32, 0.73; p = 0.001). In addition, metformin was associated with lower risks of cancer-specific mortality.
The findings of this study support the hypothesis that metformin improves the survival for cancer patients with concurrent diabetes, particularly for breast, colorectal, ovarian, and endometrial cancer. Further investigation is warranted.